The bridge between Boehringer Ingelheim's Research & Development people
and academia has been built by the Research Institute of Molecular Pathology (IMP) in Vienna, Austria where
over 200 scientists from 30 countries are carrying out basic biomedical research.
|
IMP Building in Vienna, Austria
The Research Institute
of Molecular Pathology, established in 1985,
belongs to the global Boehringer Ingelheim Group. Since
1998, the IMP has formed the core of the present Vienna
Biocenter Campus. The Institute investigates the molecular processes in the
development of organisms and the origin of disease. The
results often enable the development of new drugs at
Boehringer Ingelheim.
IMP's success is documented in a high number of scientific
publications each year. In 2007 alone, more than 90 IMP
papers were published in high impact journals. The number of
patent applications has grown to 90, all of which are at the
disposal of Boehringer Ingelheim. IMP scientists receive
frequent recognition in form of significant awards. |
|
|
The IMP Research Report gives an overview of the working
groups and scientific services at the IMP.
Images
Building
Director of the IMP,
Barry Dickson
|
